4.7 Article

Metabotropic glutamate receptor antagonists: Novel therapeutics for nicotine dependence and depression?

Journal

BIOLOGICAL PSYCHIATRY
Volume 61, Issue 1, Pages 17-22

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2006.03.053

Keywords

-

Funding

  1. NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062527] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011946, R56DA011946] Funding Source: NIH RePORTER
  3. NIDA NIH HHS [R01 DA11946, R56 DA011946] Funding Source: Medline
  4. NIMH NIH HHS [R01 MH62527] Funding Source: Medline

Ask authors/readers for more resources

Nicotine dependence is the primary motivational factor perpetuating the tobacco smoking habit that is one of the leading preventable causes of morbidity throughout the world. This Neuroscience Perspectives article summarizes and discusses recent evidence demonstrating the critical role of glutamate transmission in nicotine dependence and emerging data suggesting that compounds acting as antagonists at metabotropic glutamate receptors may be useful therapeutics to assist people in achieving and maintaining abstinence from tobacco smoking. Metabotropic glutamate 5 receptor antagonists may be useful in decreasing the reinforcing effects of nicotine, reducing motivation for nicotine and preventing relapse during protracted abstinence, whereas metabotropic glutamate 2/3 receptor antagonists may alleviate the depression observed during the early nicotine withdrawal phase. Metabotropic glutamate 2/3 receptor antagonists may also be therapeutics for non-drug-induced depressions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available